表观遗传修饰酶的变构调节。
Allosteric regulation of epigenetic modifying enzymes.
作者信息
Zucconi Beth E, Cole Philip A
机构信息
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205, USA.
出版信息
Curr Opin Chem Biol. 2017 Aug;39:109-115. doi: 10.1016/j.cbpa.2017.05.015. Epub 2017 Jul 6.
Abstract
Epigenetic enzymes including histone modifying enzymes are key regulators of gene expression in normal and disease processes. Many drug development strategies to target histone modifying enzymes have focused on ligands that bind to enzyme active sites, but allosteric pockets offer potentially attractive opportunities for therapeutic development. Recent biochemical studies have revealed roles for small molecule and peptide ligands binding outside of the active sites in modulating the catalytic activities of histone modifying enzymes. Here we highlight several examples of allosteric regulation of epigenetic enzymes and discuss the biological significance of these findings.
摘要
包括组蛋白修饰酶在内的表观遗传酶是正常和疾病过程中基因表达的关键调节因子。许多针对组蛋白修饰酶的药物开发策略都集中在与酶活性位点结合的配体上，但别构口袋为治疗开发提供了潜在的诱人机会。最近的生化研究揭示了小分子和肽配体在活性位点之外结合对调节组蛋白修饰酶催化活性的作用。在这里，我们重点介绍表观遗传酶别构调节的几个例子，并讨论这些发现的生物学意义。
相似文献
1
Allosteric regulation of epigenetic modifying enzymes.表观遗传修饰酶的变构调节。
Curr Opin Chem Biol. 2017 Aug;39:109-115. doi: 10.1016/j.cbpa.2017.05.015. Epub 2017 Jul 6.
2
Allosteric Regulation of Chromatin-Modifying Enzymes.变构调节染色质修饰酶。
Biochemistry. 2019 Jan 8;58(1):15-23. doi: 10.1021/acs.biochem.8b00894. Epub 2018 Oct 29.
3
Engineering allosteric regulation into biological catalysts.将别构调控引入生物催化剂中。
Chembiochem. 2009 Dec 14;10(18):2824-35. doi: 10.1002/cbic.200900590.
4
Targeting epigenetic machinery: Emerging novel allosteric inhibitors.靶向表观遗传机制：新兴的新型别构抑制剂。
Pharmacol Ther. 2019 Dec;204:107406. doi: 10.1016/j.pharmthera.2019.107406. Epub 2019 Sep 12.
5
Statistical Mechanics of Allosteric Enzymes.别构酶的统计力学
J Phys Chem B. 2016 Jul 7;120(26):6021-37. doi: 10.1021/acs.jpcb.6b01911. Epub 2016 Apr 29.
6
Targeting epigenetic enzymes for drug discovery.靶向表观遗传酶的药物发现。
Curr Opin Chem Biol. 2010 Aug;14(4):505-10. doi: 10.1016/j.cbpa.2010.06.174.
7
Role of protein-protein interactions in allosteric drug design for DNA methyltransferases.蛋白质-蛋白质相互作用在 DNA 甲基转移酶变构药物设计中的作用。
Adv Protein Chem Struct Biol. 2020;121:49-84. doi: 10.1016/bs.apcsb.2019.12.005. Epub 2020 Jan 10.
8
Allosteric Communication Disrupted by a Small Molecule Binding to the Imidazole Glycerol Phosphate Synthase Protein-Protein Interface.小分子与咪唑甘油磷酸合酶蛋白-蛋白界面结合破坏变构通讯
Biochemistry. 2016 Nov 29;55(47):6484-6494. doi: 10.1021/acs.biochem.6b00859. Epub 2016 Nov 11.
9
Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.催化组蛋白赖氨酸残基修饰的酶的抑制剂：结构、功能与活性
Future Med Chem. 2016 May;8(8):879-97. doi: 10.4155/fmc-2016-0021. Epub 2016 May 13.
10
Searching for new allosteric sites in enzymes.寻找酶中的新变构位点。
Curr Opin Struct Biol. 2004 Dec;14(6):706-15. doi: 10.1016/j.sbi.2004.10.009.
引用本文的文献
1
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.基于多组学和人工智能驱动的女性恶性肿瘤表观遗传治疗药物重新定位
J Transl Med. 2025 Jul 25;23(1):837. doi: 10.1186/s12967-025-06856-x.
2
Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A.酞嗪酮衍生物作为人DNA甲基转移酶3A变构抑制剂的结构研究
ACS Med Chem Lett. 2024 Apr 8;15(5):590-594. doi: 10.1021/acsmedchemlett.3c00528. eCollection 2024 May 9.
3
The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities.赖氨酸特异性去甲基化酶4A在癌症中的新作用：对肿瘤发生的影响及治疗机会
Genes Dis. 2023 Mar 23;11(2):645-663. doi: 10.1016/j.gendis.2022.12.020. eCollection 2024 Mar.
4
Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.组蛋白甲基转移酶DOT1L作为实体瘤治疗中一个有前景的表观遗传靶点。
Front Genet. 2022 Apr 13;13:864612. doi: 10.3389/fgene.2022.864612. eCollection 2022.
5
Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs.组蛋白赖氨酸甲基转移酶的别构调控：从特定环境的调控到选择性药物。
Biochem Soc Trans. 2021 Apr 30;49(2):591-607. doi: 10.1042/BST20200238.
6
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.靶向 p300/CBP 的溴结构域和乙酰转移酶活性位点的联合作用。
Biochemistry. 2019 Apr 23;58(16):2133-2143. doi: 10.1021/acs.biochem.9b00160. Epub 2019 Apr 11.
7
Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.组蛋白 H3 与组蛋白去甲基酶 KDM5A 的 PHD1 结构域结合，使活性位点发生重塑。
Nat Commun. 2019 Jan 9;10(1):94. doi: 10.1038/s41467-018-07829-z.
8
Modulating the masters: chemical tools to dissect CBP and p300 function.调控主控子：解析 CBP 和 p300 功能的化学工具。
Curr Opin Chem Biol. 2018 Aug;45:195-203. doi: 10.1016/j.cbpa.2018.06.005. Epub 2018 Jul 17.
9
Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.发现一种高选择性的组蛋白赖氨酸去甲基酶 KDM2/7 的细胞活性抑制剂。
Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15555-15559. doi: 10.1002/anie.201706788. Epub 2017 Nov 7.
本文引用的文献
1
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.强效选择性KDM5抑制剂可阻止转录起始位点处H3K4me3的细胞去甲基化及MM1S骨髓瘤细胞的增殖。
Cell Chem Biol. 2017 Mar 16;24(3):371-380. doi: 10.1016/j.chembiol.2017.02.006. Epub 2017 Mar 2.
2
Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.发现一种强效、细胞渗透、选择性的 p300/CBP 相关因子（PCAF）/一般控制不可抑制 5（GCN5）溴结构域化学探针。
J Med Chem. 2017 Jan 26;60(2):695-709. doi: 10.1021/acs.jmedchem.6b01566. Epub 2017 Jan 9.
3
Discovery of a PCAF Bromodomain Chemical Probe.发现 PCAF 溴结构域化学探针。
Angew Chem Int Ed Engl. 2017 Jan 16;56(3):827-831. doi: 10.1002/anie.201610816. Epub 2016 Dec 14.
4
Metabolic regulation of gene expression through histone acylations.通过组蛋白酰化对基因表达进行代谢调控。
Nat Rev Mol Cell Biol. 2017 Feb;18(2):90-101. doi: 10.1038/nrm.2016.140. Epub 2016 Dec 7.
5
The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation.KDM5家族在脂肪细胞分化过程中对于促增殖细胞周期基因的激活是必需的。
Nucleic Acids Res. 2017 Feb 28;45(4):1743-1759. doi: 10.1093/nar/gkw1156.
6
The GCN5-CITED2-PKA signalling module controls hepatic glucose metabolism through a cAMP-induced substrate switch.GCN5-CITED2-PKA 信号模块通过 cAMP 诱导的底物转换控制肝脏葡萄糖代谢。
Nat Commun. 2016 Nov 22;7:13147. doi: 10.1038/ncomms13147.
7
The Activation of c-Src Tyrosine Kinase: Conformational Transition Pathway and Free Energy Landscape.c-Src 酪氨酸激酶的激活：构象转变途径和自由能景观。
J Phys Chem B. 2017 Apr 20;121(15):3352-3363. doi: 10.1021/acs.jpcb.6b08409. Epub 2016 Oct 28.
8
Chemical Inhibition of Protein Methyltransferases.蛋白质甲基转移酶的化学抑制。
Cell Chem Biol. 2016 Sep 22;23(9):1067-1076. doi: 10.1016/j.chembiol.2016.07.014. Epub 2016 Aug 25.
9
KDM5A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis.KDM5A在骨质疏松症期间控制骨形态发生蛋白2诱导的骨髓间充质干细胞成骨分化。
Cell Death Dis. 2016 Aug 11;7(8):e2335. doi: 10.1038/cddis.2016.238.
10
Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.含溴结构域配体I-CBP112对核小体p300/CBP乙酰化的调节作用
Biochemistry. 2016 Jul 12;55(27):3727-34. doi: 10.1021/acs.biochem.6b00480. Epub 2016 Jul 1.
Zotero 插件